Nov 07, 2017
Market Access Impact: Non-Small Cell Lung Cancer (US) 2017
Oct 31, 2017
Avella selected by AstraZeneca to distribute CALQUENCE® (acalabrutinib)
Sep 26, 2017
OncoBEAM[TM] EGFR Kit (RUO) at Jessenius Medical Faculty of Comenius University and its University Hospital, in Martin, Slovakia
Sep 11, 2017
Results from the INJOURNEY(TM) trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
Aug 03, 2017
Mirati Therapeutics Reports Second Quarter 2017 Financial Results
Aug 02, 2017
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- After Failure of One or More Lines of Systemic Therapy
Jul 25, 2017
Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
Jun 24, 2017
European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids
Jun 15, 2017
Feinstein Institute Scientist Recognized for Innovative Chronic Lymphocytic Leukemia Research
Jun 05, 2017
Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017
Jun 05, 2017
Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up
Jun 05, 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients